A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors.

Smith, D. C.,Eisenberg, P. D.,Manikhas, G.,Chugh, R.,Gubens, M. A.,Stagg, R. J.,Kapoun, A. M.,Xu, L.,Dupont, J.,Sikic, B.; Clin. Cancer Res.. 2014 Oct 18.

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab.

Schwartzberg, L. S.,Tauer, K. W.,Hermann, R. C.,Makari-Judson, G.,Isaacs, C.,Beck, J. T.,Kaklamani, V.,Stepanski, E. J.,Rugo, H. S.,Wang, W.,Bell-McGuinn, K.,Kirshner,...; Clin. Cancer Res.. 2013 May 15.

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma.

Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., Ottesen, L...; J Clin Oncol. 2013 Jan 10.